Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Edor Kabashi wins the International Medicine PG Award for Amyotrophic Lateral Sclerosis (ALS) research

Published on: 26/10/2016 Reading time: 1 min
Edor Kabashi
Retour à la recherche

The Paulo Gontijo Institute awarded the International Medicine PG Award to Edor Kabashi, team leader at the Brain and Spine Institute – Institut du Cerveau, for his research on the development of new models and new therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

Edor Kabashi joined the Brain and Spine Institute - Institut du Cerveau - ICM in 2011 as the “Treatment of Amyotrophic lateral sclerosis: from genetics to zebrafish” team leader. He obtained his PhD in 2008 at McGill University and did postdoctoral work at Centre of Excellence in Neuromics at University of Montreal. He received many awards, including the Brain Star Award of CIHR Institute of Neuroscience in 2009 and 2011, and the Young investigator award from European Network for the Cure of ALS in 2015.

The International Medicine PG Award is an initiative of the Paulo Gontijo Institute to foster the research of young researchers around the world to promote the cure of ALS.

Selected from 15 studies, Kabashi’s studies have provided a breakthrough in developing new models and therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

 

“My team works to better understand how a variety of genetic mutations can cause motor neuron degeneration in ALS. We take advantage of a simple vertebrate model, zebrafish where one or several genes can be manipulated. Using this paradigm, we have described that several major ALS genes interact together and function in common pathways and we are currently identifying drugs which could affect these molecular targets”, says Edor Kabashi.

 

The International Medicine PG Award is recognized by the international scientific community. Its partners the International Alliance of ALS, Motor Neuron Disease Association (MNDA) and the European Community for research for the cure of ALS (ENCALS). The study results will be presented at opening ceremony of the 26th International Symposium on ALS / MND (motor neuron disease) to be held in Dublin (Ireland) in December.

Our news on the subject

Deux nouvelles certifications pour les plateformes de l’Institut du Cerveau
Two new certifications for Paris Brain Institute’s core facilities
Paris Brain Institute’s core facilities were recently awarded two new certifications: ISO 9001 certification for ICM.Quant and ISO 20387 certification for its DNA & Cell Bank.
11.14.2025 Institutional
La dépression résistante possède une signature moléculaire spécifique
Treatment-resistant depression identified as a distinct molecular subtype
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave...
11.03.2025 Research, science & health
Invincibles ensemble
Invincibles ensemble!: the growing success of a solidarity concert for ALS research
On Wednesday 15 October 2025, the mythical stage of the Olympia hosted the concert “Invincibles ensemble!” for its second edition. Twenty artists have mobilized to fight amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease.
10.16.2025 Support
La qualité des mitochondries durant le neurodéveloppement est cruciale pour la santé cérébrale
Mitochondrial quality during neurodevelopment is crucial for brain health
The anomalies underlying neurodegenerative diseases may arise during development—decades before the first symptoms appear. This hypothesis is gaining traction thanks to a new study published in Nature Communications. According to researchers from the...
10.20.2025 Research, science & health
sequencage adn
Intellectual development disorders: two new genes under the microscope
A Franco-German international research team has identified two new genes that play a role in the onset of intellectual development disorders (IDD), also known as intellectual disabilities. Researchers have successfully developed two new types of test...
12.08.2025 Research, science & health
Troubles du Développement Intellectuel
The "RNU-Splice" project receives support from the health sponsorship of AXA Mutuals
Intellectual development disorders (IDD) affect 2 to 3 per cent of the population and are characterized by impaired cognitive functions, impacting learning. TDI thus has an impact on coping skills with implications for daily life and is a major...
10.08.2025 Support
See all our news